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The adipocyte-derived hormone adiponectin pro-
motes metabolic and cardiovascular health. Circu-
lating adiponectin increases in lean states such as
caloric restriction (CR), but the reasons for this
paradox remain unclear. Unlike white adipose tissue
(WAT), bone marrow adipose tissue (MAT) increases
during CR, and both MAT and serum adiponectin in-
crease in many other clinical conditions. Thus, we
investigated whether MAT contributes to circulating
adiponectin. We find that adiponectin secretion is
greater fromMAT than WAT. Notably, specific inhibi-
tion of MAT formation in mice results in decreased
circulating adiponectin during CR despite unaltered
adiponectin expression in WAT. Inhibiting MAT for-
mation also alters skeletal muscle adaptation to CR,
suggesting that MAT exerts systemic effects. Finally,
we reveal that both MAT and serum adiponectin in-
crease during cancer therapy in humans. These ob-
servations identify MAT as an endocrine organ that
contributes significantly to increased serum adipo-
nectinduringCRandperhaps in other adverse states.
INTRODUCTION
White adipose tissue (WAT) is a major endocrine organ that
exerts diverse systemic effects. One of the most extensively368 Cell Metabolism 20, 368–375, August 5, 2014 ª2014 Elsevier Incstudied adipocyte-secreted factors is the hormone adiponectin,
which promotes insulin sensitivity, fat oxidation, antiatherogenic,
and anticancer effects (Ye and Scherer, 2013). Serum adiponec-
tin is also a well-established biomarker for insulin resistance and
cardiovascular disease; indeed, circulating adiponectin is low in
obese, insulin-resistant individuals and other adverse metabolic
states (Ye and Scherer, 2013). Conversely, serum adiponectin
increases in lean, insulin-sensitive states such as with calorie re-
striction (CR) in animals and anorexia nervosa (AN) in humans
(Combs et al., 2003; Dolezalova et al., 2007; Pannacciulli et al.,
2003). Reduced circulating adiponectin in obesity most likely de-
rives from decreased adiponectin expression and secretion,
which may result from mitochondrial dysfunction or aberrantly
increased inflammation, hypoxia, or endoplasmic reticulum
stress (Ye and Scherer, 2013). Far less is known about why
serum adiponectin increases in lean states. Although some
studies report increased adiponectin expression in WAT during
extensive CR (Qiao et al., 2011), most studies in mice and
humans find that prolonged CR or extensive weight loss in-
creases serum adiponectin without affecting adiponectin
expression or secretion from WAT (Behre et al., 2007; Combs
et al., 2003; Kovacova et al., 2009; Wang et al., 2006). Indeed,
adiponectin expression in WAT decreases in human subjects
with AN (Dolezalova et al., 2007). Adiponectin clearance is also
unaltered during CR (Qiao et al., 2011). Thus, in lean states
such as CR or AN, the paradoxical increase in serum adiponectin
can occur without greater expression or secretion from WAT or
decreased adiponectin clearance.
Our knowledge of adiponectin derives from extensive study of
WAT biology over the past generation. In comparison, metabolic
research has largely neglected another adipose depot, bone.
Table 1. MAT, WAT, BMD, and Serum Adiponectin in Subjects
with Anorexia Nervosa and Healthy Controls
HC AN p Value
Age (years)* 27.8 ± 4.6 30.3 ± 6.8 0.46
Body mass (kg) 61.7 ± 6.1 49.0 ± 5.2 <0.0001
IBW percentage 100.4 ± 5.4 79.2 ± 4.9 <0.0001
BMI (kg/m2) 22.3 ± 1.6 17.3 ± 1.3 <0.0001
Body fat percentage 27 ± 4.7 18.8 ± 5.5 <0.001
Total fat mass (kg) 17.1 ± 3.6 9.9 ± 3.2 <0.001
Total body BMD* 1.11 ± 0.10 0.97 ± 0.07 <0.001
L4 MAT* 0.53 ± 0.26 0.86 ± 0.36 <0.01
Metaphysis MAT 2.20 ± 0.87 3.93 ± 2.38 0.04
Diaphysis MAT 4.08 ± 2.76 6.76 ± 2.95 <0.02
Estimated MAT mass (kg) 2.16 ± 0.24 2.90 ± 0.21 <0.0001
MAT as a percentage of
total fat mass
13.0 ± 2.7 31.5 ± 9.2 <0.0001
Total adiponectin (ng/ml)* 6,396 ± 1,864 9,573 ± 5,291 <0.03
HMW adiponectin (ng/ml)* 3,735 ± 1,476 6,406 ± 4,139 <0.01
Subjects with AN (n = 12) and HCs (n = 21) were characterized as
described in the Experimental Procedures and Supplemental Informa-
tion. Data are mean ±SD. Asterisks indicate that a Wilcoxon rank-sum
test was used to compare these data because they were nonnormally
distributed. IBW, ideal body weight.
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Marrow Adipose Is a Key Source of Adiponectinmarrow adipose tissue (MAT). Bone marrow (BM) adipocytes
were identified over a century ago, and MAT accounts for
approximately 70% of BM volume in adult humans (Fazeli
et al., 2013). In striking contrast toWAT,MATmarkedly increases
during CR in animals, including humans (Devlin, 2011). Thus, in
this manuscript, we investigate the hypothesis that MAT is a
source of circulating adiponectin in states of leanness. We pro-
vide direct evidence that MAT is required for maximal increases
in serum adiponectin during CR.
RESULTS
Anorexia Nervosa Is Associated with Increased Serum
Adiponectin and MAT
Previous studies have not assessed both serum adiponectin and
BM adiposity in a single cohort of AN subjects. Thus, we
completed both analyses in a group of AN subjects and healthy
controls (HC). Body mass index (BMI), adiposity and bone min-
eral density (BMD) were significantly lower in AN compared to
HC subjects (Table 1). AN subjects had significantly higher
MAT of the L4 vertebrae, femoral metaphysis and femoral diaph-
ysis, and increased total and high molecular weight (HMW)
serum adiponectin, despite decreased total fat mass (Table 1).
Additional calculations revealed that MAT comprised 13.0% of
total adipose mass in HC subjects and 31.5% in AN subjects.
This striking increase strongly suggests that, during CR,MAT ex-
ists in an amount that has clear potential to exert systemic effects
through secretion of endocrine factors such as adiponectin.
The Relative Expression and Secretion of Adiponectin Is
Greater from MAT than from WAT
The ability of MAT to express or secrete adiponectin has not
been addressed. To do so, we took advantage of the fact that,Celin mice, BM of lumbar vertebrae (LV) contains few adipocytes,
whereas BMof caudal vertebrae (CV) is almost entirelyMAT (Fig-
ure 1A). We found that adiponectin expression in CV of C57BL/
6J mice was similar to that in inguinal WAT (iWAT), gonadal
WAT (gWAT), and perirenal WAT (pWAT; Figure 1B). In contrast,
expression of peroxisome proliferator-activated receptor g
(PPARg) was similar between WAT and CV of some mice but
much lower in CV of other mice. Other adipocyte proteins,
such as fatty acid binding protein 4 (FABP4) and perilipin A,
were also markedly decreased in CV in comparison to WAT,
whereas hormone-sensitive lipase (HSL) expression was unde-
tectable in CV (Figure 1B). Similar results were observed in
C3H/HeJ mice (Figure S1A available online). However, because
CV also contain many nonadipocyte populations, expression of
adipocyte proteins in CV lysates might be diluted in comparison
to that in WAT. Therefore, we next analyzed pure MAT from rab-
bit tibiae, in which there is a gradient of increasing adiposity from
proximal to distal (Figure 1C). This pattern of MAT distribution,
which is also typical of that in humans (Scheller and Rosen,
2014), allowed us to isolate intact pieces of pure MAT or red
marrow (RM). No trabecular bone was observed in any of the
MAT samples (Figure 1D). As in mice, adiponectin protein was
robustly expressed in rabbit MAT relative to FABP4 and perilipin
A (Figure 1E); this was also observed for Adipoq and Fabp4 tran-
scripts (Figure S1B). Expression of Pparg was similar between
MAT andWAT, whereas Cebpa and Lepwere lower in MAT (Fig-
ure S1B). These observations suggest that, in comparison to
WAT, CV of mice and MAT of rabbits express adiponectin at
disproportionately high levels relative to other typical adipocyte
transcripts and proteins.
To investigate the ability of MAT to secrete adiponectin, we
cultured rabbit MAT and WAT explants and analyzed adiponec-
tin secretion into conditioned media. We found that MAT
secreted adiponectin at levels far higher than WAT despite
similar media total protein content (Figures 1F and S1C).
To test whether these observations extend to humans, we
characterized WAT and MAT from three patients undergoing
below-the-knee amputation. Unlike rabbit MAT, bone fragments
were interspersed with MAT in two of the three samples (Fig-
ure 1G). Nevertheless, adiponectin expression was greater in
MAT than WAT of these patients (Figure 1H). Strikingly, adipo-
nectin secretion was also markedly higher from explants of
MAT than WAT despite a similar degree of explant breakdown
and total protein content of the conditioned media (Figures 1I
and S1D). These results suggest that human tibial MAT has a
greater capacity than WAT to both express and secrete
adiponectin.
MAT Directly Contributes to Increased Serum
Adiponectin during CR
The above results are consistent with our hypothesis that MAT is
a source of circulating adiponectin. However, our observations
in AN subjects are correlative; therefore, we next directly tested
whether MAT expansion is required for increased serum adipo-
nectin with CR. To do so, we used Ocn-Wnt10b mice, which
overexpress Wnt10b from osteoblasts (Bennett et al., 2007).
Wnt10b potently inhibits adipogenesis and causes high bone
mass; hence, we hypothesized that Ocn-Wnt10b mice would
resist MAT expansion with CR, allowing us to test whetherl Metabolism 20, 368–375, August 5, 2014 ª2014 Elsevier Inc. 369
Figure 1. Relative Expression and Secretion of Adiponectin Is Greater from MAT than WAT
(A and B) iWAT, gWAT, pWAT, LV (for red marrow), and CV (for MAT) were isolated from male C57BL/6J mice.
(A) Micrographs of H&E-stained tissue sections.
(B) Immunoblots of total protein lysates from tissues of three mice. ERK1/ERK2 is a loading control. Phosphorylated forms of HSL and perilipin A appear as
multiple bands.
(C–F) WAT, RM, and MAT were isolated from New Zealand white rabbits.
(C) Image of a bisected tibia showing the typical distribution of MAT.
(D) Micrographs of H&E-stained tissue sections.
(E) Immunoblots of total protein lysates from two rabbits, representative of four rabbits. a-tubulin is a loading control.
(F) Immunoblots and silver stain of conditioned media from WAT and MAT explants from one rabbit, representative of seven rabbits.
(G–I) Tibial MAT and scWAT were isolated from patients undergoing lower limb amputation.
(G) Micrographs of H&E-stained tissue sections.
(H) Immunoblots of total protein lysates of each tissue. a-tubulin is a loading control.
(I) Immunoblots and silver stain of conditioned media from explants of scWAT and MAT from patient 3. Lamins A and C were analyzed as an estimate of explant
breakdown. Similar results were obtained for explants from patients 1 and 2 (Figure S1).
In (F) and (I), silver staining was used to assess total protein content. Images in (A)–(D) are representative of ten mice or rabbits. For micrographs, scale bars
represent 200 mm. See also Figure S1.
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Marrow Adipose Is a Key Source of Adiponectinincreased MAT is required for elevated serum adiponectin in this
context. We fed wild-type (WT) and Ocn-Wnt10b mice a control
or 30% CR diet for 6 weeks. In female mice of both genotypes,370 Cell Metabolism 20, 368–375, August 5, 2014 ª2014 Elsevier IncCR significantly decreased body mass, blood glucose, lean
mass, and liver mass but not fat mass (Figure S2A–S2C and
2A). Though not intuitive, this preservation of fat mass in female.
Figure 2. Blocking MAT Expansion Directly Prevents Increased Circulating Adiponectin during CR
WT and Ocn-Wnt10b mice were fed ad libitum or a 30% CR diet from 9–15 weeks of age.
(A) Masses of iWAT, gWAT, and BAT in 15-week-old mice.
(B and C) BM adiposity was assessed by osmium tetroxide staining of tibiae followed by mCT analysis.
(B) Representative images of stained tibiae. The scale bar represents 1 mm.
(C) MAT as a percentage of marrow volume (MV) was determined from mCT scans.
(D) Analysis of HMW, MMW, LMW, and total adiponectin in sera of 15-week-old mice. Immunoblots are from the same exposure of film.
(E) Quantitation of serum adiponectin from (D).
(F and G) qPCR analysis of Adipoq expression in iWAT, gWAT, or combined tibiae and femurs (Tib/Fem).
(H–J) Total RNA and protein was isolated from quadricepsmuscle. Expression ofPgc1a, Tfam, andAcadmwas determined by qPCR (H). Protein phosphorylation
was determined by immunoblotting (I) and quantified by densitometry (J). CaMKIIa phosphorylation is a marker of Ca2+/calmodulin signaling. Data are
mean ±SEM of the following numbers of mice: WT, n = 6; Wnt10b, n = 4; WT CR, n = 5; and Wnt10b CR, n = 6. Similar results were observed in a second mouse
cohort. For each diet group, significant differences between WT and Wnt10b mice are indicated by *p <0.05, **p <0.01, or ***p <0.001. Within each genotype,
significant differences between ad libitum and CR diets are indicated by ##p <0.01 or ###p <0.001.
See also Figures S2 and S3 and Table S1.
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Marrow Adipose Is a Key Source of AdiponectinC57BL/6J mice is consistent with previous CR studies (Li et al.,
2010; Varady et al., 2010). Other expected effects of CR on WAT
were also noted, including increased expression of fatty acidCelsynthase protein (FAS) and transcripts (Fasn) (Figure S2D–S2F)
(Bruss et al., 2010). Importantly, neither body mass nor fat
mass differed between WT and Ocn-Wnt10b mice on eitherl Metabolism 20, 368–375, August 5, 2014 ª2014 Elsevier Inc. 371
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Marrow Adipose Is a Key Source of Adiponectindiet. In contrast, Ocn-Wnt10b mice had markedly increased
bone mass (Figure S2G and Table S1), consistent with our previ-
ous studies (Bennett et al., 2007). Next, we used osmium tetrox-
ide staining to assess BM adiposity (Figures 2B and 2C). On a
control diet, MAT did not significantly differ between WT and
Ocn-Wnt10b mice. CR markedly increased MAT in WT mice;
however, this increase was significantly blunted in Ocn-
Wnt10b mice. Further analysis of whole tibiae and femurs re-
vealed that CR increased expression of the adipocyte markers
Fabp4, Pparg, and Lep in bones of WT mice but not in Ocn-
Wnt10bmice (Figure S2H). Thus, both osmium tetroxide staining
and quantitative PCR (qPCR) demonstrate that Ocn-Wnt10b
mice resist MAT expansion during CR. Strikingly, CR-associated
increases in serum adiponectin were also significantly blunted in
Ocn-Wnt10b mice. HMW adiponectin was decreased by more
than 50% in CR-fed Ocn-Wnt10b mice, and total, medium
molecular weight (MMW), and low molecular weight (LMW) adi-
ponectin were similarly decreased (Figures 2D and 2E). These
differences are unlikely to be caused by differential hemocon-
centration (Naruse et al., 2005), because silver staining re-
vealed similar total serum protein content across all four groups
(data not shown). We cannot exclude the possibility that
adiponectin secretion from WAT is lower in Ocn-Wnt10b
mice; however, WAT expression of Gstk1, Erp44, and Erol1,
which encode regulators of adiponectin secretion (Ye and
Scherer, 2013), was unaffected by CR or transgenic Wnt10b
(Figure S2F; data not shown). These data are consistent with
the finding that adiponectin secretion from WAT is unaltered
during CR (Kovacova et al., 2009). Importantly, neither CR
nor transgenic Wnt10b affected expression of Adipoq tran-
scripts or protein in WAT (Figures 2F, S2D, and S2E). Thus,
altered adiponectin expression in WAT does not account for
the observed differences in serum adiponectin. In contrast,
Adipoq expression in tibiae and femurs mirrored the changes
in serum adiponectin (Figure 2G), suggesting that circulating
adiponectin levels are directly related to adiponectin produc-
tion from MAT. Therefore, these results provide direct evidence
that MAT expansion is necessary for maximal production of
serum adiponectin during CR.
Impaired MAT Expansion Alters Skeletal Muscle
Adaptations to CR
Next, we investigated whether limiting the increases in MAT or
adiponectin during CR has wider metabolic consequences. In
obese states, lack of adiponectin causes glucose intolerance
(Maeda et al., 2002; Ye and Scherer, 2013). However, glucose
tolerance did not differ between WT and Ocn-Wnt10b mice (Fig-
ure S2I). This is consistent with adiponectin deficiency not
affecting glucose tolerance in lean mice (Maeda et al., 2002).
Expected effects of adiponectin or CR on liver transcript
expression, including increased Pparg, Ppara, and Hnf4a and
decreased Fabp5 (Liu et al., 2012; Nogueira et al., 2012), also
did not differ between WT and Ocn-Wnt10b mice (Figure S3).
Therefore, we next analyzed skeletal muscle, a major metabolic
target of adiponectin. Here, adiponectin stimulates Ca2+ influx
and LKB1 activation, thereby enhancing AMPK activity, PPARg
coactivator 1a expression, and mitochondrial biogenesis (Ye
and Scherer, 2013). Consistent with a previous report (Finley
et al., 2012), in WT mice CR increased expression of Pgc1a372 Cell Metabolism 20, 368–375, August 5, 2014 ª2014 Elsevier Incand its downstream targets Tfam and Acadm (Figure 2H), which
encode proteins with important mitochondrial functions. Strik-
ingly, these effects of CR were absent in Ocn-Wnt10b mice (Fig-
ure 2H). In contrast, hepatic expression of Pgc1a and Tfam did
not differ between genotypes (Figure S3), suggesting that con-
sequences of impaired MAT expansion are specific to skeletal
muscle. As reported elsewhere (Gonzalez et al., 2004), CR in
WT mice did not affect steady-state AMPK activity in muscle
(Figures 2I and 2J). Two pathways upstream of AMPK activa-
tion, LKB1, and Ca2+/calmodulin signaling, were also unaf-
fected by CR in WT mice (Figures 2I and 2J). In contrast, CR
markedly activated AMPK and CaMKIIa in skeletal muscle of
Ocn-Wnt10b mice without affecting LKB1 activity (Figures 2I
and 2J). These observations demonstrate that blocking MAT
expansion during CR alters local homeostatic adaptations in
skeletal muscle.
Both MAT and Circulating Adiponectin Increase during
Cancer Therapy in Humans
The above findings in humans, rabbits, and mice identify MAT as
a key source of circulating adiponectin during CR. Next, we
began to explore this relationship in other clinical conditions.
BM adiposity increases during radiotherapy or chemotherapy
for cancer (Georgiou et al., 2012); hence, we hypothesized that
serum adiponectin might also increase during such treatments.
To address this possibility, we analyzed MAT and serum adipo-
nectin in patients undergoing therapy for ovarian or endometrial
cancer. We found that both LV MAT and total serum adiponectin
increased significantly at 6 and 12 months after onset of chemo-
therapy or radiotherapy, despite no change in total body fat (Fig-
ures 3A–3D). Thus, both MAT and serum adiponectin increase
during cancer therapy without changes in total adiposity outside
of the BM. This suggests thatMATmight contribute to circulating
adiponectin in contexts beyond CR.
DISCUSSION
Previous studies have investigated BM adipocytes as local reg-
ulators of skeletal remodeling (Scheller and Rosen, 2014); how-
ever, the present study identifies MAT as an endocrine organ
that can exert systemic effects. We show that, in comparison
to WAT, CV of mice and MAT of rabbits express adiponectin
more highly than other adipocyte markers. Moreover, we reveal
that secretion of adiponectin is far greater from MAT than from
WAT of rabbits and humans. Our observations in AN subjects
show that MAT can make up over 30% of total body fat, under-
scoring the notion that, during CR in humans, MAT exists in
amounts sufficient to make a major contribution to circulating
adiponectin. Conclusive evidence comes from our use of Ocn-
Wnt10b mice as a model of specific MAT ablation. We show
that, with CR, thesemice resist increases in bothMAT and serum
adiponectin without differences in WAT mass or adiponectin
expression in WAT. It should be noted that, in some contexts,
CR can increase adiponectin expression in WAT (Qiao et al.,
2011); however, our findings are consistent with previous studies
(Behre et al., 2007; Combs et al., 2003; Dolezalova et al., 2007;
Kovacova et al., 2009), which collectively suggest that elevated
circulating adiponectin during CR can occur without increased
adiponectin production from WAT. Notably, our results in.
Figure 3. Both MAT and Serum Adiponectin
Increase during Cancer Therapy in Humans
MAT, serum adiponectin, and body fat percentage
were assessed in patients undergoing radio-
therapy for endometrial cancer or chemotherapy
for ovarian cancer.
(A) Representative MRI images of two patients
before and at six months posttreatment. Arrows
highlight increased vertebral MAT (signal fat frac-
tion; sFF) posttreatment.
(B) MAT was determined by water-fat MRI at the
indicated time points. Data are mean ±SEM of 11–
15 patients.
(C) Total serum adiponectin concentrations were
determined by ELISA and are mean ±SEM of 8–11
patients, with 11 patients assessed at baseline
and 6 months, and eight of these patients also
assessed at 12 months.
(D) Body fat percentage, as determined by DXA,
shown as mean ±SEM of 11 patients.
For (B–D), statistically significant differences
between baseline and 6 or 12 months posttreat-
ment are indicated by *p < 0.05 or **p < 0.01.
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Marrow Adipose Is a Key Source of AdiponectinOcn-Wnt10b mice greatly extend these earlier studies by
providing direct evidence that MAT is a key source of circulating
adiponectin during CR. Thus, adiponectin production from MAT
may account, at least in part, for the adiponectin paradox.
By producing adiponectin, MAT has the potential to exert
systemic effects on metabolic homeostasis, immune responses,
vascular function, or cancer risk. Indeed, we find that impaired
MAT expansion during CR leads to altered metabolic adapta-
tions in skeletal muscle, suggesting thatMAT has effects beyond
the skeleton. However, whether these effects are driven
by changes in circulating adiponectin remains unclear. For
example, the CR-associated increase in Pgc1a, Tfam, and
Acadm in muscle of WT, but not Ocn-Wnt10b, mice, is consis-
tent with the differences in circulating adiponectin, whereas
increased AMPK and CaMKIIa activation with CR in Ocn-
Wnt10b, but not WT mice, is highly unexpected. One possibility
is that skeletal muscle of Ocn-Wnt10bmice adaptsmetabolically
to a relative adiponectin deficiency by sustaining Ca2+/calmod-
ulin and AMPK activation. However, even in WT mice, skeletal
muscle AMPK activity does not increase during CR (Figures 2I
and 2J) (Gonzalez et al., 2004) despite increased circulating adi-
ponectin. This suggests that, during CR, adiponectin does not
stimulate AMPK in muscle. Indeed, existing knowledge of adi-
ponectin action is largely limited to the context of obesity and in-
sulin resistance (Ye and Scherer, 2013); the role of adiponectin
during CR is poorly understood. In addition to adiponectin, we
show that rabbit MAT expresses leptin at similar levels to iWAT
and pWAT, and silver staining of human MAT- and WAT-condi-
tioned media indicates that these tissues have distinct secretory
profiles. These observations suggest that unique endocrine
functions of MAT extend beyond adiponectin.
Finally, we reveal that both MAT and circulating adiponectin
increase in patients undergoing cancer therapy. On the basis
of these findings, it is tempting to speculate that the increased
adiponectin derives from MAT expansion. Given that low circu-
lating adiponectin is associated with increased cancer risk and
that adiponectin can limit tumor growth (Dalamaga et al.,Cel2012), the consequences of elevated adiponectin during cancer
therapy clearly warrant further investigation. Beyond cancer,
many other conditions are associated with increases in both
MAT and circulating adiponectin, including aging, estrogen defi-
ciency, type 1 diabetes, and treatment with pharmacologic
agents such as thiazolidinediones or fibroblast growth factor
21 (Combs et al., 2003; Fazeli et al., 2013; Isobe et al., 2005;
Kharitonenkov et al., 2007; Scheller and Rosen, 2014; Wei
et al., 2012; Ye and Scherer, 2013). This suggests that MAT
might impact upon circulating adiponectin in other clinically rele-
vant conditions. In addition, both circulating adiponectin and
MAT volume inversely correlate with BMD in human populations
(Richards et al., 2007; Shen et al., 2012). This suggests that MAT
might positively associate with circulating adiponectin in non-
pathological contexts, as recently reported in Caucasian girls
(Newton et al., 2013).
In summary, we have found that MAT expansion contributes
significantly to increased serum adiponectin and skeletal muscle
adaptation during CR. These findings suggest that MAT is a
major source of circulating adiponectin in states of leanness
and show that, through endocrine functions, MAT can act
beyond the skeleton to exert systemic effects. However, the
consequences of adiponectin production from MAT are yet to
be fully established, and much about MAT biology remains
unknown. Thus, future research in this area is clearly warranted
if we are to better understand this understudied, clinically rele-
vant tissue.EXPERIMENTAL PROCEDURES
Additional procedures are described in the Supplemental Information.Human Subjects
All work was performed as approved by the institutional review boards (IRBs)
of the relevant institutions, as follows: AN study, Partners Human Research
Office IRB; cancer therapy study, University of Minnesota IRB; human MAT
studies, University of Michigan IRB.l Metabolism 20, 368–375, August 5, 2014 ª2014 Elsevier Inc. 373
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All procedures were approved by the University of Michigan Committee on the
Use and Care of Animals. C57BL/6J (000664) and C3H/HeJ (000659) mice
were from the Jackson Laboratory. Ocn-Wnt10bmice (C57BL/6J background)
were described previously (Bennett et al., 2007). Mice were housed on a 12 hr
light/dark cycle in the Unit for Laboratory Animal Medicine at the University of
Michigan with free access to water and, as indicated, food. Random-fed blood
glucose, body fat, lean mass, and free fluid were assessed as described pre-
viously (Mori et al., 2012). For serum adiponectin, blood was taken from the tail
vein of mice or the marginal ear artery of rabbits with Microvette CB300 capil-
lary tubes (Sarstedt). Male New Zealand white rabbits, used at 11–18 weeks in
age, were from Harlan Laboratories.
Caloric Restriction
Mice were fed a control diet (Research Diets, D12450B) or 30% CR diet
(Research Diets, D10012703) from 9–15weeks of age, as described previously
(Devlin et al., 2010). Food was administered daily. The CR diet restricts macro-
nutrient intake while maintaining mineral and vitamin levels. Mice were single
housed from 8–9 weeks of age in order to determine average daily ad libitum
food intake prior to CR.
Tissues
Tissues were fixed in 10%neutral-buffered formalin. Bones were decalcified in
14% EDTA for 14 days. Paraffin-embedded tissue sections were processed
and stained with hematoxylin and eosin (H&E) or Toluidine blue, as indicated.
Statistical Analysis
Statistical analysis was performed with JMP 9.0 (SAS Institute), SPSS (IBM), or
GraphPad Prism 6 (GraphPad Software), with means of normally distributed
data compared with a two-tailed Student’s t test and means of nonnormally
distributed data compared with the Wilcoxon test. Significant differences
in transcript expression of rabbit tissues were assessed with a paired
Student’s t test. Significant differences between WT and Ocn-Wnt10b mice
were assessed with a two-sample Student’s t test or ANOVA with post tests,
as appropriate. Significant differences between MAT, serum adiponectin, and
body fat percentage of human subjects undergoing cancer therapy were
assessed with a Wilcoxon matched-pair signed rank test, with comparisons
made between baseline and 6 or 12 months posttreatment. Error bars in the
figures represent SEM. For all comparisons, a p value of < 0.05was considered
statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information contains Supplemental Experimental Procedures,
three figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.cmet.2014.06.003.
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